Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
European Journal of Cancer2016Vol. 67, pp. 66–72
Citations Over TimeTop 10% of 2016 papers
Saskia Herz, Thomas Höfer, Matina Papapanagiotou, Julia Leyh, Sarah Meyenburg, Dirk Schadendorf, Selma Ugurel, Alexander Roesch, Elisabeth Livingstone, Bastian Schilling, Cindy Franklin
Related Papers
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma(2019)17 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis(2020)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)